Skip to main content
Book Chapter

Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma

  • Bennett M
  • Pitson S
  • Wallington-Beddoe C
DOI: 10.1007/978-3-030-73440-4_4
N/ACitations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The first clinically available proteasome inhibitor (PI) bortezomib was trialed in multiple myeloma (MM) approximately two decades ago and has since become a mainstay of myeloma therapy, significantly enhancing the overall survival of patients. However, bortezomib...

Cite

CITATION STYLE

APA

Bennett, M. K., Pitson, S. M., & Wallington-Beddoe, C. T. (2021). Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma (pp. 39–59). https://doi.org/10.1007/978-3-030-73440-4_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free